Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma ( GEN 503): final results of an open‐label, phase 1/2 study-Reference-Cited by-同舟云学术

Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma ( GEN 503): final results of an open‐label, phase 1/2 study

Published:2019-03-31 Issue: Volume: Page:
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Plesner Torben¹^ORCID,Arkenau Hendrik‐Tobias²,Gay Francesca³,Minnema Monique C.⁴,Boccadoro Mario³,Moreau Philippe⁵^ORCID,Cavenagh Jamie⁶,Perrot Aurore⁷,Laubach Jacob P.⁸^ORCID,Krejcik Jakub¹,Ahmadi Tahamtan⁹,Boer Carla¹⁰,Chen Diana¹¹,Chiu Christopher¹²,Schecter Jordan M.¹³,Richardson Paul G.⁸^ORCID

Affiliation:

1. Vejle Hospital and University of Southern Denmark VejleDenmark

2. Sarah Cannon Research Institute University College London Cancer Institute LondonUnited Kingdom

3. Myeloma Unit Division of Hematology University of Torino TorinoItaly

4. Department of Hematology UMC Utrecht Cancer Centre UtrechtThe Netherlands

5. Department of Hematology University Hospital Hôtel‐Dieu NantesFrance

6. Department of Haemato‐Oncology St Bartholomew's Hospital Barts Health NHS Trust LondonUnited Kingdom

7. Hematology Department University Hospital Vandoeuvre Les NancyFrance

8. The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center Department of Medical Oncology Dana‐Farber Cancer Institute Harvard Medical School Boston MA USA

9. Genmab US Inc. Princeton NJUSA

10. Janssen Biologics Leiden The Netherlands

11. Janssen Research & Development Shanghai China

12. Janssen Research & Development Spring House PA USA

13. Janssen Research & Development Raritan NJ USA

Funder

Janssen Research and Development

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.15879

Reference6 articles.

1. Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma

2. Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

3. Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma

4. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1

5. US Department of Health and Human Services National Institutes of Health & National Cancer Institute. (2010)Common Terminology Criteria for Adverse Events (CTCAE). Version 4.03.https://www.eortc.be/services/doc/ctc/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf(accessed July 11 2018).

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Daratumumab Treatment for “Truly Frail” Elderly Myeloma Patients;Life;2024-03-15

2. Epstein–Barr Virus Driven Hodgkin’s Lymphoma after a Short Course of Daratumumab Treatment for Relapsed Multiple Myeloma;Case Reports in Hematology;2023-12-18

3. Management of Relapsed–Refractory Multiple Myeloma in the Era of Advanced Therapies: Evidence-Based Recommendations for Routine Clinical Practice;Cancers;2023-04-05

4. Natural killer cell therapy for hematologic malignancies: successes, challenges, and the future;Stem Cell Research & Therapy;2021-03-25

5. Monoclonal Antibodies: Leading Actors in the Relapsed/Refractory Multiple Myeloma Treatment;Pharmaceuticals;2020-11-27